Human hepatocytes display substantial functional inter-individual variation regarding drug metabolizing functions. In order to investigate if this diversity is mirrored in hepatocytes derived from different human pluripotent stem cell (hPSC) lines, we evaluated 25 hPSC lines originating from 24 different donors for hepatic differentiation and functionality. Homogenous hepatocyte cultures could be derived from all hPSC lines using one standardized differentiation procedure. To the best of our knowledge this is the first report of a standardized hepatic differentiation procedure that is generally applicable across a large panel of hPSC lines without any adaptations to individual lines. Importantly, with regard to functional aspects, such as Cytochrome P450 activities, we observed that hepatocytes derived from different hPSC lines displayed inter-individual variation characteristic for primary hepatocytes obtained from different donors, while these activities were highly reproducible between repeated experiments using the same line. Taken together, these data demonstrate the emerging possibility to compile panels of hPSC-derived hepatocytes of particular phenotypes/genotypes relevant for drug metabolism and toxicity studies. Moreover, these findings are of significance for applications within the regenerative medicine field, since our stringent differentiation procedure allows the derivation of homogenous hepatocyte cultures from multiple donors which is a prerequisite for the realization of future personalized stem cell based therapies.
This is a preview of subscription content, access via your institution.
Buy single article
Instant access to the full article PDF.
Tax calculation will be finalised during checkout.
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
Tax calculation will be finalised during checkout.
Kola, I., & Landis, J. (2004). Can the pharmaceutical industry reduce attrition rates? Nature Reviews Drug Discovery, 3, 711–715.
Lee, W. M. (2003). Acute liver failure in the United States. Seminars in Liver Disease, 23, 217–226.
Hewitt, N. J., Gomez-Lechon, M. J., Houston, J. B., et al. (2007). Primary hepatocytes: current understanding of the regulation of metabolic enzymes and transporter proteins, and pharmaceutical practice for the use of hepatocytes in metabolism, enzyme induction, transporter, clearance, and hepatotoxicity studies. Drug Metabolism Reviews, 39, 159–234.
Gomez-Lechon, M. J., Donato, M. T., Castell, J. V., et al. (2004). Human hepatocytes in primary culture, the choice to investigate drug metabolism in man. Current Drug Metabolism, 5, 443–462.
Li, A. P., Lu, C., Brent, J. A., et al. (1999). Cryopreserved human hepatocytes: characterization of drug-metabolizing enzyme activities and applications in higher throughput screening assays for hepatotoxicity, metabolic stability, and drug-drug interaction potential. Chemico-Biological Interactions, 121, 17–35.
Richert, L., Liguori, M. J., Abadie, C., et al. (2006). Gene expression in human hepatocytes in suspension after isolation is similar to the liver of origin, is not affected by hepatocyte cold storage and cryopreservation, but is strongly changed after hepatocyte plating. Drug Metabolism and Disposition, 34, 870–879.
Rodriguez-Antona, C., Donato, M. T., Boobis, A., et al. (2002). Cytochrome P450 expression in human hepatocytes and hepatoma cell lines: molecular mechanisms that determine lower expression in cultured cells. Xenobiotica, 32, 505–520.
Gerets, H. H. J., Tilmant, K., Gerin, B., et al. (2012). Characterization of primary human hepatocytes, HepG2 cells and HepaRG cells at the mRNA level and CYP activity in response to inducers and their predictivity for the detection of human hepatotoxins. Cell Biology and Toxicology, 28, 69–87.
Thomson, J. A., Itskovitz-Eldor, J., Shapiro, S. S., et al. (1998). Embryonic stem cell lines derived from human blastocysts. Science, 282, 1145–1147.
Takahashi, K., Tanabe, K., Ohnuki, M., et al. (2007). Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell, 131, 861–872.
Baxter, M. A., Rowe, C., Alder, J., et al. (2010). Generating hepatic cell lineages from pluripotent stem cells for drug toxicity screening. Stem Cell Research, 5, 4–22.
Sartipy, P., & Björquist, P. (2011). Concise review: human pluripotent stem cell-based models for cardiac and hepatic toxicity assessment. Stem Cells, 29, 744–748.
Li, A. P. (2008). Human hepatocytes as an effective alternative experimental system for the evaluation of human drug properties: general concepts and assay procedures. ALTEX, 25, 33–42.
Ek, M., Söderdahl, T., Küppers-Munther, B., et al. (2007). Expression of drug metabolizing enzymes in hepatocyte-like cells derived from human embryonic stem cells. Biochemical Pharmacology, 74, 496–503.
Söderdahl, T., Küppers-Munther, B., Heins, N., et al. (2007). Glutathione transferases in hepatocyte-like cells derived from human embryonic stem cells. Toxicology In Vitro, 21, 929–937.
Hay, D. C., Fletcher, J., Payne, C., et al. (2008). Highly efficient differentiation of human embryonic stem cells to functional hepatic endoderm requires Activin A and Wnt3a signaling. Proceedings of the National Academy of Sciences of the United States of America, 105, 2301–2306.
Hay, D. C., Zhao, D., Fletcher, J., et al. (2008). Efficient differentiation of hepatocytes from human embryonic stem cells exhibiting markers recapitulating liver development in vivo. Stem Cells, 26, 894–902.
Song, Z., Cai, J., Liu, Y., et al. (2009). Efficient generation of hepatocyte-like cells from human induced pluripotent stem cells. Cell Research, 19, 1233–1242.
Basma, H., Soto-Gutiérrez, A., Yannam, G. R., et al. (2009). Differentiation and transplantation of human embryonic stem cell-derived hepatocytes. Gastroenterology, 136, 990–999.
Brolen, G., Sivertsson, L., Björquist, P., et al. (2010). Hepatocyte-like cells derived from human embryonic stem cells specifically via definitive endoderm and a progenitor stage. Journal of Biotechnology, 145, 84–94.
Duan, Y., Ma, X., Zou, W., et al. (2010). Differentiation and characterization of metabolically functioning hepatocytes from human embryonic stem cells. Stem Cells, 28, 674–686.
Si-Tayeb, K., Noto, F. K., Nagaoka, M., et al. (2010). Highly efficient generation of human hepatocyte-like cells from induced pluripotent stem cells. Hepatology, 51, 297–305.
Sullivan, G. J., Hay, D. C., Park, I. H., et al. (2010). Generation of functional human hepatic endoderm from human induced pluripotent stem cells. Hepatology, 51, 329–335.
Touboul, T., Hannan, N. R., Corbineau, S., et al. (2010). Generation of functional hepatocytes from human embryonic stem cells under chemically defined conditions that recapitulate liver development. Hepatology, 51, 1754–1765.
Rashid, S. T., Corbineau, S., Hannan, N., et al. (2010). Modeling inherited metabolic disorders of the liver using human induced pluripotent stem cells. Journal of Clinical Investigation, 120, 3127–3136.
Ghodsizadeh, A., Taei, A., Totonchi, M., et al. (2010). Generation of liver disease-specific induced pluripotent stem cells along with efficient differentiation to functional hepatocyte-like cells. Stem Cell Reviews and Reports, 6, 622–632.
Yildirimman, R., Brolén, G., Vilardell, M., et al. (2011). Human embryonic stem cell derived hepatocyte-like cells as a tool for in vitro hazard assessment of chemical carcinogenicity. Toxicological Sciences, 124, 278–290.
Funakoshi, N., Duret, C., Pascussi, J. M., et al. (2011). Comparison of hepatic-like cell production from human embryonic stem cells and adult liver progenitor cells: CAR transduction activates a battery of detoxification genes. Stem Cell Reviews, 7, 518–531.
Ulvestad, M., Nordell, P., Asplund, A., et al. (2013). Drug metabolizing enzyme and transporter protein profiles of hepatocytes derived from human embryonic and induced pluripotent stem cells. Biochemical Pharmacology, 86, 691–702.
Kajiwara, M., Aoi, T., Okita, K., et al. (2012). Donor-dependent variations in hepatic differentiation from human induced pluripotent stem cells. Proceedings of the National Academy of Sciences of the United States of America, 109, 12538–12543.
Hannan, N. R., Segeritz, C. P., Touboul, T., et al. (2013). Production of hepatocyte-like cells from human pluripotent stem cells. Nature Protocols, 8, 430–437.
Hannan, N. R., Fordham, R. P., Syed, Y. A., et al. (2013). Generation of multipotent foregut stem cells from human pluripotent stem cells. Stem Cell Reports, 1, 293–306.
Mikkola, M., Olsson, C., Palgi, J., et al. (2006). Distinct differentiation characteristics of individual human embryonic stem cell lines. BMC Developmental Biology, 6, 40.
Osafune, K., Caron, L., Borowiak, M., et al. (2008). Marked differences in differentiation propensity among human embryonic stem cell lines. Nature Biotechnology, 3, 313–315.
Itaba, N., Wairagu, P. M., Aramaki, N., et al. (2014). Nuclear receptor gene alteration in human induced pluripotent stem cells with hepatic differentiation propensity. Hepatology Research, 44(14), 408–439.
Bock, C., Kiskinis, E., Verstappen, G., et al. (2011). Reference maps of human embryonic and induced pluripotent stem cell variation enable high-throughput characterization of pluripotent cell lines. Cell, 144, 439–452.
Heins, N., Englund, M. C., Sjöblom, C., et al. (2004). Derivation, characterization, and differentiation of human embryonic stem cells. Stem Cells, 22, 367–370.
Sjögren-Jansson, E., Zetterström, M., Moya, K., et al. (2005). Large-scale propagation of four undifferentiated human embryonic stem cell lines in a feeder-free culture system. Developmental Dynamics, 233, 1304–1314.
Caisander, G., Park, H., Frej, K., et al. (2006). Chromosomal integrity maintained in five human embryonic stem cell lines after prolonged in vitro culture. Chromosome Research, 14, 131–137.
Aguilar-Gallardo, C., Poo, M., Gomez, E., et al. (2010). Derivation, characterization, differentiation, and registration of seven human embryonic stem cell lines (VAL-3, -4, -5, -6M, -7, -8, and -9) on human feeder. In Vitro Cellular and Developmental Biology - Animal, 46, 317–326.
Funa, N. S., Schachter, K. A., Lerdrup, M., et al. (2015). Beta-Catenin regulates primitive streak induction through collaborative interactions with SMAD2/SMAD3 and OCT4. Cell Stem Cell, 16(6), 639–652.
Holmgren, G., Sjögren, A. K., Barragan, I., et al. (2014). Long-term chronic toxicity testing using human induced pluripotent stem cell-derived hepatocytes. Drug Metabolism and Disposition, 42, 1401–1406.
Sartipy, P. (2013). Advancing pluripotent stem cell culture: it is a matter of setting the standard. Stem Cells and Development, 22, 1159–1161.
Kim, K., Doi, A., Wen, B., et al. (2010). Epigenetic memory in induced pluripotent stem cells. Nature, 467, 285–290.
Ohi, Y., Qin, H., Hong, C., et al. (2011). Incomplete DNA methylation underlies a transcriptional memory of somatic cells in human induced pluripotent stem cells. Nature Cell Biology, 13, 541–549.
Bar-Nur, O., Russ, H. A., Efrat, S., et al. (2011). Epigenetic memory and preferential lineage-specific differentiation in induced pluripotent stem cell-derived from human beta-cells. Cell Stem Cell, 9, 17–23.
Lee, S. B., Seo, D., Choi, D., et al. (2012). Contribution of hepatic lineage stage-specific donor memory to the differential potential of induced mouse pluripotent stem cells. Stem Cells, 30, 997–1007.
Ponsoda, X., Pareja, E., Gomez-Lechon, M. J., et al. (2001). Drug biotransformation by human hepatocytes. In vitro/in vivo metabolism by cells from the same donor. Journal of Hepatology, 34, 19–25.
Kuehl, P., Zhang, J., Lin, Y., et al. (2001). Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nature Genetics, 27, 383–391.
Takayama, K., Morisaki, Y., Kuno, S., et al. (2014). Prediction of interindividual differences in hepatic functions and drug sensitivity by using human induced pluripotent stem cell-derived hepatocytes. Proceedings of the National Academy of Sciences of the United States of America, 111, 16772–16777.
We thank other members of Takara Bio Europe AB and Skövde University who have provided assistance and technical help through-out this project.
Supported by the IMI-JU project MIP-DILI (grant 115336), the Seventh Framework Program project InnovaLiv (grant 278152), and the Knowledge Foundation (grants 2010/0069, 2012/0310, 2013/89).
Disclosure of Potential Conflicts of Interest
All authors are or have been employed by Takara Bio Europe AB (former Cellartis AB) when this study was performed.
Annika Asplund: Collection, assembly, analysis, and interpretation of data, manuscript writing.
Anders Aspegren: Conception and design, data analysis and interpretation.
Arvind Pradip, Mariska van Giezen, Marie Rehnström, Susanna Jacobsson, Nidal Ghosheh, Dorra El Hajjam, Sandra Holmgren, Susanna Larsson, Jörg Benecke, Mariela Butron, Annelie Wigander: Collection, assembly and analysis of data.
Helena Choukair, Karin Noaksson: Analysis and interpretation of data.
Peter Sartipy, Josefina Edsbagge: Interpretation of data, manuscript writing.
Petter Björquist: Conception and design, manuscript writing.
Barbara Küppers-Munther: Conception and design, assembly, analysis, and interpretation of data, manuscript writing.
All: Final approval of manuscript
About this article
Cite this article
Asplund, A., Pradip, A., van Giezen, M. et al. One Standardized Differentiation Procedure Robustly Generates Homogenous Hepatocyte Cultures Displaying Metabolic Diversity from a Large Panel of Human Pluripotent Stem Cells. Stem Cell Rev and Rep 12, 90–104 (2016). https://doi.org/10.1007/s12015-015-9621-9
- Hepatocyte differentiation
- Human induced pluripotent stem cells
- Human embyronic stem cells
- Cellular therapy